FDA panels plan September reviews of anemia drug safety

07/19/2007 | Boston Globe (tiered subscription model), The

FDA advisory panels plan to meet in September on anemia drugs made by Johnson & Johnson and Amgen to look at safety issues, including potential fatalities. One panel is to examine J&J's Procrit for patients with anemia caused by kidney failure, the other Amgen's Epogen and Aranesp, both for the same indication.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC